Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | fatty acid elongase, putative | 0.0206 | 0 | 0.5 |
Leishmania major | fatty acid elongase, putative | 0.0206 | 0 | 0.5 |
Schistosoma mansoni | hormone-sensitive lipase (S09 family) | 0.0462 | 1 | 0.5 |
Plasmodium falciparum | long chain fatty acid elongation enzyme, putative | 0.0206 | 0 | 0.5 |
Trypanosoma cruzi | fatty acid elongase, putative | 0.0206 | 0 | 0.5 |
Plasmodium vivax | GNS1/SUR4 domain containing protein | 0.0206 | 0 | 0.5 |
Brugia malayi | Fatty acid elongation protein 3 | 0.0206 | 0 | 0.5 |
Toxoplasma gondii | GNS1/SUR4 family protein | 0.0206 | 0 | 0.5 |
Trypanosoma brucei | Fatty acid elongase | 0.0206 | 0 | 0.5 |
Schistosoma mansoni | hormone-sensitive lipase (S09 family) | 0.0462 | 1 | 0.5 |
Schistosoma mansoni | hormone-sensitive lipase (S09 family) | 0.0462 | 1 | 0.5 |
Brugia malayi | GNS1/SUR4 family protein | 0.0206 | 0 | 0.5 |
Plasmodium falciparum | fatty acid elongation protein, GNS1/SUR4 family, putative | 0.0206 | 0 | 0.5 |
Trypanosoma cruzi | fatty acid elongase, putative | 0.0206 | 0 | 0.5 |
Trypanosoma cruzi | fatty acid elongase, putative | 0.0206 | 0 | 0.5 |
Toxoplasma gondii | integral membrane protein, GNS1/SUR4 family protein, putative | 0.0206 | 0 | 0.5 |
Echinococcus multilocularis | hormone sensitive lipase | 0.0462 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0462 | 1 | 1 |
Trypanosoma cruzi | fatty acid elongase, putative | 0.0206 | 0 | 0.5 |
Leishmania major | fatty acid elongase, putative | 0.0206 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.